Bioprocessing - Upstream & Downstream

The analytical complexities that come with oligonucleotide manufacturing are difficult, but not impossible.

Here’s how an mRNA-based approach can overcome the development challenges of designing protein therapeutics.

Four approaches to address the challenge of producing complex therapeutics in standard cell lines.

Who deserves a place on our annual list of inspirational and influential industry professionals?

An expert from Samsung Biologics offers her perspective on the future of antibody drug conjugates.

NervGen President and CEO Mike Kelly discusses the potential of the company’s investigational drug NVG-291 for spinal cord injury.

How metabolic conditioning could improve cell therapy potency and persistence.

Cryogenic freezing performed too fast can damage biopharma products. What’s the best way forward? An expert gives their view.

Progress in Alzheimer’s Disease research, but a cure will take time. Delaying it and disseminating that research may buy scientists the time they need

Biopharma tech continues to advance so why is downstream processing such a headache?